Eisai Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eisai Co., Ltd.
The announcement that LEAP-006 and LEAP-008, both in non-small cell lung cancer, did not meet their primary endpoints adds to a string of failures for the combination.
A new digital health venture set up by Eisai plans to start operations in Japan from April 2024 with services related to cognitive impairment and dementia, in line with the Japanese firm's therapeutic advances in this area.
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.
China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.
- Other Names / Subsidiaries
- EA Pharma Co., Ltd.
- Eisai China Inc
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Jingyi Weixiang (Shanghai) Health Industry Development Limited
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.
- Eisai Vietnam Co., Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.